3 Stocks Moving The Drugs Industry Upward
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
All three major indices are trading up today with the
Dow Jones Industrial Average
(
^DJI
) trading up 111 points (0.6%) at 18,244 as of Monday, March 2, 2015, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,773 issues advancing vs. 1,212 declining with 168 unchanged.
The Drugs industry currently sits up 0.9% versus the S&P 500, which is up 0.4%. Top gainers within the industry include
(
), up 4.7%,
(
), up 4.0%,
(
), up 3.1%,
(
), up 2.6% and
(
), up 2.6%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Actavis is up $3.64 (1.2%) to $295.00 on average volume. Thus far, 1.4 million shares of Actavis exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $292.80-$296.24 after having opened the day at $293.16 as compared to the previous trading day's close of $291.36.
Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. Actavis has a market cap of $77.2 billion and is part of the health care sector. Shares are up 13.2% year-to-date as of the close of trading on Friday. Currently there are 15 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
Actavis
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
2. As of noon trading,
(
) is up $0.76 (0.7%) to $103.27 on light volume. Thus far, 2.6 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 9.2 million shares. The stock has ranged in price between $102.70-$103.37 after having opened the day at $102.89 as compared to the previous trading day's close of $102.51.
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $285.8 billion and is part of the health care sector. Shares are down 2.0% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Johnson & Johnson
as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
Johnson & Johnson Ratings Report
now.
1. As of noon trading,
(
) is up $0.40 (1.1%) to $34.72 on light volume. Thus far, 9.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.5 million shares. The stock has ranged in price between $34.06-$34.76 after having opened the day at $34.06 as compared to the previous trading day's close of $34.32.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $217.9 billion and is part of the health care sector. Shares are up 10.2% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.
TheStreet Ratings rates
Pfizer
as a
. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null